Noninvasive prenatal testing of α-thalassemia and β-thalassemia through population-based parental haplotyping

Genome Med. 2021 Feb 5;13(1):18. doi: 10.1186/s13073-021-00836-8.

Abstract

Background: Noninvasive prenatal testing (NIPT) of recessive monogenic diseases depends heavily on knowing the correct parental haplotypes. However, the currently used family-based haplotyping method requires pedigrees, and molecular haplotyping is highly challenging due to its high cost, long turnaround time, and complexity. Here, we proposed a new two-step approach, population-based haplotyping-NIPT (PBH-NIPT), using α-thalassemia and β-thalassemia as prototypes.

Methods: First, we deduced parental haplotypes with Beagle 4.0 with training on a large retrospective carrier screening dataset (4356 thalassemia carrier screening-positive cases). Second, we inferred fetal haplotypes using a parental haplotype-assisted hidden Markov model (HMM) and the Viterbi algorithm.

Results: With this approach, we enrolled 59 couples at risk of having a fetus with thalassemia and successfully inferred 94.1% (111/118) of fetal alleles. We confirmed these alleles by invasive prenatal diagnosis, with 99.1% (110/111) accuracy (95% CI, 95.1-100%).

Conclusions: These results demonstrate that PBH-NIPT is a sensitive, fast, and inexpensive strategy for NIPT of thalassemia.

Keywords: Haplotypes; NIPT; Population-based haplotyping; Recessive monogenic diseases; α-Thalassemia; β-Thalassemia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genetics, Population
  • Haplotypes / genetics*
  • Humans
  • Noninvasive Prenatal Testing*
  • Parents*
  • Sample Size
  • alpha-Thalassemia / genetics*
  • beta-Thalassemia / genetics*